Profound Research, a leading clinical trial site network, today announced the key leadership appointment of Michael Shipton as Chief Commercial Officer, a move aimed at driving innovation and continued growth.  

Shipton brings extensive experience to his new role. He most recently served as Chief Commercial Officer at Science 37, where he led transformative initiatives and overhauled their go-to-market strategy, resulting in increased market competitiveness. As a proven commercial strategist, Shipton has over three decades of experience designing, implementing, and delivering customized business solutions. All in all, Shipton has a broad track record of success in steering large global teams to address intricate business challenges. 

“I am honored to join an organization that understands how commercial growth in our vertical market can directly enrich patient lives by expanding access to innovative treatments and advancing scientific progress,” said Shipton.  

Lora Parahovnik, PhD, Chief Executive Officer of Profound Research, shared her excitement about the appointment, stating, "We are delighted to welcome Michael Shipton as our Chief Commercial Officer. His expertise and leadership will be pivotal in advancing Profound Research as an industry leader focused on medical innovation and enhancing patient access to treatments.” 

About Profound Research 

Profound Research is an integrated clinical research network comprising trial sites embedded into independent physician practices. With a mission to expand access to clinical research for community patients and offer more therapeutic options to community physicians, Profound Research operates across Southern California, the Detroit metropolitan area, and is expanding nationwide. The company boasts a team of experienced research professionals dedicated to providing high-quality clinical research support to physicians and their patients.